← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Degarelix

FDA approved · Rx

GnRH receptor antagonist

Also known as: Firmagon, FE-200486 (free base), FE200486 ANHYDROUS FREE BASE, FE-200486 ANHYDROUS FREE BASE, degarelixum

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 170 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Degarelix, sold as Firmagon, is a synthetic peptide that blocks gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. By blocking these receptors, it reduces release of luteinizing hormone and follicle-stimulating hormone, which in turn lowers testosterone production without the initial surge seen with GnRH agonists.

What the evidence shows

Automatic summaryHuman trials

Degarelix is FDA approved for the treatment of advanced prostate cancer, supported by a large body of clinical research including about 170 registered human trials reaching Phase 4. Its use outside this approved indication is not established.

Key facts

Molecular formula
C82H103ClN18O16
Molecular weight
1632.3 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

170registered studies
Phase 4most advanced phase
57completed (sample)
9recruiting (sample)

Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma

Phase 2CompletedNCT04391556

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

Phase 2CompletedNCT01751451

TRial on the Endocrine Activity of Neoadjuvant Degarelix

Phase 2CompletedNCT02005887

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

Phase 2RecruitingNCT07313241

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

404papers referencing Degarelix

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

BJU Int2008

A new model of patient tumor-derived breast cancer xenografts for preclinical assays.

Clin Cancer Res2007

Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.

Clin Cancer Res2023

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.

Circulation2021

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.